Table.
Baseline Characteristics of All ASPREE Participants and Those Taking Regular Aspirin (2 or More Days Per Week) Before Enrollment, by Randomly Assigned Treatment
| Characteristic | All ASPREE Participants | Participants Included in This Study | ||
|---|---|---|---|---|
| Total | Placebo (Cessation) |
Aspirin (Continuation) | ||
| Participants, n | 19 114 | 1714 | 841 | 873 |
| Age | ||||
| Median (IQR), y | 74.0 (71.6–77.7) | 74.4 (71.8–78.4) | 74.5 (71.8–78.3) | 74.3 (71.6–78.5) |
| ≥75 y, n (%) | 7951 (41.6) | 777 (45.3) | 385 (45.8) | 392 (44.9) |
| Female, n (%) | 5373 (56.4) | 941 (54.9) | 447 (53.2) | 494 (56.6) |
| Country, n (%) | ||||
| Australia | 16 703 (87.4) | 1018 (59.4) | 505 (60.1) | 513 (58.8) |
| United States | 2411 (12.6) | 696 (40.6) | 336 (40.0) | 360 (41.2) |
| Ethnicity/race, n (%)* | ||||
| White | 17 450 (91.3) | 1335 (77.9) | 659 (78.4) | 676 (77.4) |
| Black | 901 (4.7) | 262 (15.3) | 131 (15.6) | 131 (15.0) |
| Hispanic/Latino | 488 (2.6) | 90 (5.3) | 40 (4.8) | 50 (5.7) |
| Other | 275 (1.4) | 27 (1.6) | 11 (1.3) | 16 (1.8) |
| Mean BMI (SD), kg/m2 | 28.1 (4.8) | 28.8 (5.0) | 28.6 (5.0) | 28.9 (5.0) |
| Smoking status, n (%) | ||||
| Never | 10 580 (55.4) | 892 (52.0) | 443 (52.7) | 449 (51.4) |
| Previous | 7799 (40.8) | 750 (43.8) | 356(42.3) | 394 (45.1) |
| Current | 735 (3.8) | 72 (4.2) | 42 (5.0) | 30 (3.4) |
| Diabetes mellitus, n (%)† | 2057 (10.8) | 325 (19.0) | 164 (19.5) | 161 (18.4) |
| Hypertension, n (%)‡ | 14 213 (74.4) | 1354 (79.0) | 660 (78.5) | 694 (79.5) |
| Dyslipidemia, n (%)§ | 12 467 (65.2) | 1096 (63.9) | 548 (65.2) | 548 (62.8) |
| Chronic kidney disease, n (%)∥ | 4920 (25.7) | 488 (28.5) | 254 (30.2) | 234 (26.8) |
| CVD risk factors, n (%)¶ | ||||
| 0–1 | 8678 (45.4) | 704 (41.1) | 339 (40.3) | 365 (41.8) |
| 2 | 8808 (46.1) | 750 (43.8) | 374 (44.5) | 376 (43.1) |
| 3–4 | 1628 (8.5) | 260 (15.2) | 128 (15.2) | 132 (15.1) |
| Personal history of cancer, n (%) | 1827 (19.2) | 347 (20.3) | 160 (19.0) | 187 (21.4) |
| Use of statins, n (%) | 5987 (31.3) | 719 (42.0) | 355 (42.2) | 364 (41.7) |
| Pretrial aspirin use, n (%)** | ||||
| Dose, mg | ||||
| ≤100 | – | 1519 (88.6) | 741 (88.1) | 778 (89.1) |
| 325 | – | 94 (5.5) | 45 (5.4) | 49 (5.6) |
| 500 | – | 17 (1.0) | 9 (1.1) | 8 (0.9) |
| Unknown | – | 84 (4.9) | 46 (5.5) | 38 (4.4) |
| Regimen, d/wk | ||||
| 2–5 | – | 292 (17.0) | 145 (17.2) | 147 (16.8) |
| ≥6 | – | 1422 (83.0) | 696 (82.8) | 726 (83.2) |
| Duration, y | ||||
| <1 | – | 345 (20.1) | 175 (20.8) | 170 (19.5) |
| 1–4 | – | 679 (39.6) | 337 (40.1) | 342 (39.2) |
| 5–9 | – | 370 (21.6) | 178 (21.2) | 192 (22.0) |
| ≥10 | – | 320 (18.7) | 151 (18.0) | 169 (19.4) |
ASPREE = ASPirin in Reducing Events in the Elderly; BMI = body mass index; CVD = cardiovascular disease; IQR = interquartile range.
Ethnicity/race “Other” includes Australian Aborigine/Torres Strait Islander, Native American, more than 1 race, Native Hawaiian/Pacific Islander, and those who were not Hispanic and who did not state their ethnicity/race.
Diabetes mellitus is defined from self-report or fasting blood glucose level ≥7 mmol/L (≥126 mg/dL) or on treatment of diabetes mellitus.
Hypertension is defined as “on treatment” for high blood pressure or blood pressure >140/90 mm Hg at study entry.
Dyslipidemia is defined as those taking cholesterol-lowering medications or serum cholesterol ≥5.5 mmol/L (≥212 mg/dL; Australia) and ≥6.2 mmol/L (≥240 mg/dL; United States) or low-density lipoprotein cholesterol >4.1 mmol/L (>160 mg/dL).
Chronic kidney disease is defined as having an estimated glomerular filtration rate <60 mL/min/1.73 m2 or urinary albumin-creatinine ratio ≥30 mg/g.
Cardiovascular risk factors include the following 4 conditions: hypertension, diabetes, dyslipidemia, and current smoking.
Data regarding prior aspirin use pretrial were collected by investigators from participants (before being enrolled) via a questionnaire with the following questions (response options in parentheses): 1) Immediately prior to your involvement in ASPREE, were you taking aspirin regularly? (yes; no); if yes, 2) What dosage? (≤100 mg, 325 mg, 500 mg, unknown); 3) How often? (≤1 once per week, 2–5 days per week, ≥6 days per week); and 4) For how long? (<1, 1–4, 5–9, 10+ year(s)).